
## Karl Andersson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1984352/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Clinical Course of Alcohol Use Disorder Depicted by Digital Biomarkers. Frontiers in Digital Health, 2021, 3, 732049.	1.5	4
2	A realâ€time cellâ€binding assay reveals dynamic features of STxB–Gb3 cointernalization and STxBâ€mediated cargo delivery into cancer cells. FEBS Letters, 2020, 594, 2406-2420.	1.3	2
3	Breathalyser-Based eHealth Data Suggest That Self-Reporting of Abstinence Is a Poor Outcome Measure for Alcohol Use Disorder Clinical Trials. Alcohol and Alcoholism, 2020, 55, 237-245.	0.9	11
4	Maximum Time Between Tests: A Digital Biomarker to Detect Therapy Compliance and Assess Schedule Quality in Measurement-Based eHealth Systems for Alcohol Use Disorder. Alcohol and Alcoholism, 2019, 54, 70-72.	0.9	6
5	Real-time Monitoring using a breathalyzer-based eHealth system can identify lapse/relapse patterns in alcohol use disorder Patients. Alcohol and Alcoholism, 2018, 53, 368-375.	0.9	17
6	Detecting ligand interactions in real time on living bacterial cells. Applied Microbiology and Biotechnology, 2018, 102, 4193-4201.	1.7	3
7	Thermodynamic and kinetic approaches for evaluation of monoclonal antibody - Lipoprotein interactions. Analytical Biochemistry, 2017, 518, 25-34.	1.1	16
8	Novel Real-Time Proximity Assay for Characterizing Multiple Receptor Interactions on Living Cells. Analytical Chemistry, 2017, 89, 13212-13218.	3.2	8
9	Real-time Characterization of Antibody Binding to Receptors on Living Immune Cells. Frontiers in Immunology, 2017, 8, 455.	2.2	51
10	Impact of assay temperature on antibody binding characteristics in living cells: A case study. Biomedical Reports, 2017, 7, 400-406.	0.9	21
11	Improving the Prediction of Prostate Cancer Overall Survival by Supplementing Readily Available Clinical Data with Gene Expression Levels of IGFBP3 and F3 in Formalin-Fixed Paraffin Embedded Core Needle Biopsy Material. PLoS ONE, 2016, 11, e0145545.	1.1	8
12	Characterizing and Controlling the Loading and Release of Cationic Amphiphilic Peptides onto and from PEG-Stabilized Lipodisks. Langmuir, 2016, 32, 12091-12099.	1.6	16
13	Avidity characterization of genetically engineered T-cells with novel and established approaches. BMC Immunology, 2016, 17, 23.	0.9	15
14	Deciphering the Stepwise Binding Mode of HRG1Î <sup>2</sup> to HER3 by Surface Plasmon Resonance and Interaction Map. PLoS ONE, 2015, 10, e0116870.	1.1	8
15	Automated functional characterization of radiolabeled antibodies. Nuclear Medicine Communications, 2014, 35, 767-776.	0.5	8
16	Methods for Radiolabelling of Monoclonal Antibodies. Methods in Molecular Biology, 2014, 1060, 309-330.	0.4	40
17	Conjugation Effects on Antibody–Drug Conjugates: Evaluation of Interaction Kinetics in Real Time on Living Cells. Molecular Pharmaceutics, 2014, 11, 4154-4163.	2.3	14
18	Determination of receptor protein binding site specificity and relative binding strength using a time-resolved competition assay. Journal of Pharmacological and Toxicological Methods, 2014, 70, 145-151.	0.3	2

KARL ANDERSSON

#	Article	IF	CITATIONS
19	Operator Dependent Choice of Prostate Cancer Biopsy Has Limited Impact on a Gene Signature Analysis for the Highly Expressed Genes IGFBP3 and F3 in Prostate Cancer Epithelial Cells. PLoS ONE, 2014, 9, e109610.	1.1	10
20	Exploring Time-Resolved Characterization of the Heterogeneity and Dynamics of Ligand-Receptor Interactions on Living Cells. Journal of Analytical Oncology, 2014, 3, .	0.1	9
21	Detecting ligand interactions with G protein-coupled receptors in real-time on living cells. Biochemical and Biophysical Research Communications, 2013, 441, 820-824.	1.0	11
22	Evaluation of backbone-cyclized HER2-binding 2-helix Affibody molecule for In Vivo molecular imaging. Nuclear Medicine and Biology, 2013, 40, 378-386.	0.3	15
23	Evaluating real-time immunohistochemistry on multiple tissue samples, multiple targets and multiple antibody labeling methods. BMC Research Notes, 2013, 6, 542.	0.6	12
24	[99mTc(CO)3]+-(HE)3-ZIGF1R:4551, a new Affibody conjugate for visualization of insulin-like growth factor-1 receptor expression in malignant tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 439-449.	3.3	38
25	<i>In Vivo</i> and <i>In Vitro</i> Studies on Renal Uptake of Radiolabeled Affibody Molecules for Imaging of HER2 Expression in Tumors. Cancer Biotherapy and Radiopharmaceuticals, 2013, 28, 187-195.	0.7	30
26	Development of a rapid low cost fluorescent biosensor for the detection of food contaminants. Biosensors and Bioelectronics, 2013, 41, 96-102.	5.3	24
27	Evaluation of Real-Time Immunohistochemistry and Interaction Map as an Alternative Objective Assessment of HER2 Expression in Human Breast Cancer Tissue. Applied Immunohistochemistry and Molecular Morphology, 2013, 21, 497-505.	0.6	3
28	Resolving the EGF-EGFR interaction characteristics through a multiple-temperature, multiple-inhibitor, real-time interaction analysis approach. Molecular and Clinical Oncology, 2013, 1, 343-352.	0.4	32
29	Deciphering complex protein interaction kinetics using Interaction Map. Biochemical and Biophysical Research Communications, 2012, 428, 74-79.	1.0	37
30	Generation and Evaluation of Bispecific Affibody Molecules for Simultaneous Targeting of EGFR and HER2. Bioconjugate Chemistry, 2012, 23, 1802-1811.	1.8	26
31	Gefitinib Induces Epidermal Growth Factor Receptor Dimers Which Alters the Interaction Characteristics with 125I-EGF. PLoS ONE, 2011, 6, e24739.	1.1	77
32	Circumventing the requirement of binding saturation for receptor quantification using interaction kinetic extrapolation. Nuclear Medicine Communications, 2011, 32, 863-867.	0.5	15
33	Protein interactions with HER-family receptors can have different characteristics depending on the hosting cell line. International Journal of Oncology, 2011, 40, 1677-82.	1.4	20
34	Avoiding false negative results in specificity analysis of protein-protein interactions. Journal of Molecular Recognition, 2011, 24, 81-89.	1.1	12
35	Comparing the Epidermal Growth Factor Interaction with Four Different Cell Lines: Intriguing Effects Imply Strong Dependency of Cellular Context. PLoS ONE, 2011, 6, e16536.	1.1	46
36	Real-time immunohistochemistry analysis of embedded tissue. Applied Radiation and Isotopes, 2010, 68, 2372-2376.	0.7	6

KARL ANDERSSON

#	Article	IF	CITATIONS
37	Antibody-antigen interactions: What is the required time to equilibrium?. Nature Precedings, 2010, , .	0.1	8
38	The influence of Bz-DOTA and CHX-Aâ€3-DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules: implications for 114mIn-mediated targeting therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1460-1468.	3.3	27
39	Characterization of <sup>111</sup> In and <sup>177</sup> Luâ€labeled antibodies binding to CD44v6 using a novel automated radioimmunoassay. Journal of Molecular Recognition, 2008, 21, 179-183.	1.1	22
40	Real-time viability assay based on <sup>51</sup> Cr retention in adherent cells. BioTechniques, 2008, 44, 237-240.	0.8	7
41	Radionuclide Therapy of HER2-Positive Microxenografts Using a 177Lu-Labeled HER2-Specific Affibody Molecule. Cancer Research, 2007, 67, 2773-2782.	0.4	203
42	Label-free kinetic binding data as a decisive element in drug discovery. Expert Opinion on Drug Discovery, 2006, 1, 439-446.	2.5	26
43	Automated, high-resolution cellular retention and uptake studies in vitro. Applied Radiation and Isotopes, 2006, 64, 901-905.	0.7	70
44	Measuring the affinity of a radioligand with its receptor using a rotating cell dish with in situ reference area. Applied Radiation and Isotopes, 2006, 64, 32-37.	0.7	46
45	Replacing affinity with binding kinetics in QSAR studies resolves otherwise confounded effects. Journal of Chemometrics, 2006, 20, 370-375.	0.7	13
46	Kinetic determinations of molecular interactions using Biacore—minimum data requirements for efficient experimental design. Journal of Molecular Recognition, 2005, 18, 307-317.	1.1	75
47	[177Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 1457-1462.	3.3	61
48	Structural Modeling Extends QSAR Analysis of Antibody-Lysozyme Interactions to 3D-QSAR. Biophysical Journal, 2003, 84, 2264-2272.	0.2	25
49	QSAR studies applied to the prediction of antigen–antibody interaction kinetics as measured by BIACORE. Protein Engineering, Design and Selection, 2002, 15, 373-382.	1.0	29
50	Kinetic and Affinity Predictions of a Protein-Protein Interaction Using Multivariate Experimental Design. Journal of Biological Chemistry, 2002, 277, 29897-29907.	1.6	46
51	Predicting the kinetics of peptide-antibody interactions using a multivariate experimental design of sequence and chemical space. Journal of Molecular Recognition, 2001, 14, 62-71.	1.1	34
52	Biosensor Analysis of Drug–Target Interactions: Direct and Competitive Binding Assays for Investigation of Interactions between Thrombin and Thrombin Inhibitors. Analytical Biochemistry, 2000, 278, 1-13.	1.1	133
53	Biosensor Analysis of the Interaction between Immobilized Human Serum Albumin and Drug Compounds for Prediction of Human Serum Albumin Binding Levels. Journal of Medicinal Chemistry, 2000, 43, 1986-1992.	2.9	288
54	Kinetic characterization of the interaction of the Z-fragment of protein A with mouse-IgG3 in a volume in chemical space. , 1999, 37, 494-498.		12

#	Article	IF	CITATIONS
55	Exploring buffer space for molecular interactions. , 1999, 12, 310-315.		50